Loading patent…
AssigneesColey Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc., University of Iowa Research Foundation
InventorsGunther Hartmann, Robert L. Bratzler, Arthur M. Krieg
Estimating the term…
Methods and compositions are provided for extending the clinical utility of IFN-α in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-α treatment and reduce IFN-α treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs.
1-46. (canceled)
A method of treating a subject to activate interferon-producing cells (IPCs) of the subject comprising
55-121. (canceled)
A method of enhancing efficacy of IFN-α treatment in a subject in need of such treatment, comprising
130-139. (canceled)
A method of supporting survival of natural interferon-producing cells (IPCs) in vitro, comprising
144-200. (canceled)
An isolated nucleic acid having a sequence selected from the group consisting of:
A pharmaceutical composition comprising
Dependencies are inferred from the claim text.